$DGX

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics (DGX) reported Q3 operating income of $479M, up from $386M YoY. Adjusted EPS rose 15.4% to $3.00. The company expects full-year 2026 revenue of $12.065B-$12.105B. Quest plans to acquire select assets from a health system in the Northeastern U.S. and launched consumer health services via Apple Health app. Management addressed PAMA concerns, estimating a 1% revenue impact in 2027.

Original reporting
Published Oct 22, 2026, 6:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$DGXBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for the diagnostics market, potentially boosting related stocks.

02

Market read

First report of Q3 numbers and upgraded guidance for a large-cap healthcare company; likely to move DGX and peers.

03

What to watch

Potential PAMA regulatory impact and cybersecurity incident could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Quest Diagnostics (NYSE:DGX) disclosed Q3 operating results and raised its 2026 outlook, including revenue, EPS, cash flow, and capital spending expectations.

Company-level read

Ticker impact

$DGXBullishHigh confidence
Context

Quest Diagnostics reported Q3 results and raised full-year 2026 revenue and EPS guidance.

Expected impact

likely upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Guidance increase of 9.3‑9.7% revenue growth and EPS $10.21‑$10.31 exceeds prior expectations, supporting a bullish reaction.

Market effects

Positive earnings may lift broader healthcare diagnostics sector.

U.S. healthcare stocks could see modest gains.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

If guidance proves unsustainable, a pullback could follow.

Key entities

  • Quest Diagnostics

    Provider of diagnostic information services.

Related articles

$DGXLow

Quest Diagnostics Reports Hack on IT System Used by Clients

Quest Diagnostics reported a cyber incident involving its Quanum Lab Services Manager system, potentially compromising certain patient records. The company paused access to the system while investigating but stated it has not materially disrupted operations. Quest notified U.S. law enforcement and is taking remedial measures. The company reported $11.04 billion in revenue for 2025. This follows recent cyber incidents at Abbott Labs, which is facing lawsuits.

$DGXMed

Quest Diagnostics Inc (DGX) (Q3 2026) Earnings Call Highlights: Double-Digit Revenue

Quest Diagnostics (DGX) reported Q3 2026 earnings with double-digit revenue growth, but faces challenges. PAMA reimbursement cuts may impact 2027 revenues by 1%. Total revenue per requisition declined 4.2% due to business mix, though it rose 1.7% excluding certain relationships. The company also reported a cybersecurity incident and higher fuel costs. CEO Jim Davis and CFO Sam Samad discussed growth strategies, partnerships, and margin improvements.

$DGXHighAI 8/10

Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript

Quest Diagnostics (DGX) raised its full-year revenue and earnings guidance after Q3 2026, citing strong performance across physician, hospital, and consumer health channels. Key growth drivers include collaborations, acquisitions, and innovative solutions like Apple Health app integration. The company also announced plans to expand its Alzheimer's disease testing portfolio and improve operational efficiency through automation and AI.

$DGXMedAI 8/10

Quest Diagnostics Incorporated Q3 2026 Earnings Call Summary

Quest Diagnostics reported 10% Q3 2026 revenue growth, driven by strong performance across commercial channels and partnerships. Consumer health revenue is expected to grow over 30% for the year. The company raised full-year 2026 revenue and EPS guidance, citing sustained demand and AI-driven efficiency gains. Management discussed potential PAMA-related revenue impacts and cybersecurity incidents. They plan to offset PAMA headwinds through cost efficiencies and volume growth.